Paper39005125
Impact of Tyrosine Kinase Inhibitors (TKIs) on Growth in Children and Adolescents with Chronic Myeloid Leukemia: A Systematic Review.
Katsarou D and 5 others. Curr Pharm Des, 2024. Cited by 6 papers, by iCite.
Cite this record
ConductScience Library. Impact of Tyrosine Kinase Inhibitors (TKIs) on Growth in Children and Adolescents with Chronic Myeloid Leukemia: A Systematic Review. Papers, record 39005125. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39005125
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Impact of Tyrosine Kinase Inhibitors (TKIs) on Growth in Children and Adolescents with Chronic Myeloid Leukemia: A Systematic Review.
- PubMed
Topics7
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Protein Kinase Inhibitors | Major topic |
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | Major topic |
| Humans | |
| Child | |
| Adolescent | |
| Antineoplastic Agents | |
| Tyrosine Kinase Inhibitors |
Source PubMed
References90
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 33435150 | Chronic Myeloid Leukemia: A Model Disease of the Past, Present and Future. | Cells | 2021 | https://conductscience.org/library/papers/33435150 | PubMed |
| 2 | 35920965 | Management of Chronic Myeloid Leukemia in Children and Young Adults. | Curr Hematol Malig Rep | 2022 | https://conductscience.org/library/papers/35920965 | PubMed |
| 3 | 36485083 | Treatment of CML in pregnancy. | Hematology Am Soc Hematol Educ Program | 2022 | https://conductscience.org/library/papers/36485083 | PubMed |
| 4 | 35321439 | Management of Chronic Myeloid Leukemia and Pregnancy: A Bibliometric Analysis (2000-2020). | Front Oncol | 2022 | https://conductscience.org/library/papers/35321439 | PubMed |
| 5 | 30370478 | Chronic Myeloid Leukemia: Beyond BCR-ABL1. | Curr Hematol Malig Rep | 2018 | https://conductscience.org/library/papers/30370478 | PubMed |
| 6 | 27220498 | Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors: An Evolving Paradigm of Molecularly Targeted Therapy. | Mol Diagn Ther | 2016 | https://conductscience.org/library/papers/27220498 | PubMed |
| 7 | 32806528 | Philadelphia Chromosome-Positive Leukemia in the Lymphoid Lineage-Similarities and Differences with the Myeloid Lineage and Specific Vulnerabilities. | Int J Mol Sci | 2020 | https://conductscience.org/library/papers/32806528 | PubMed |
| 8 | 12783368 | Molecular mechanisms of transformation by the BCR-ABL oncogene. | Semin Hematol | 2003 | https://conductscience.org/library/papers/12783368 | PubMed |
| 9 | 33718985 | Chronic Myelogenous Leukemia in Childhood. | Curr Oncol Rep | 2021 | https://conductscience.org/library/papers/33718985 | PubMed |
| 10 | 19890786 | Allogeneic stem cell transplantation for pediatric and adolescent patients with CML: results from the prospective trial CML-paed I. | Klin Padiatr | 2009 | https://conductscience.org/library/papers/19890786 | PubMed |
| 11 | 25500000 | Mechanisms of resistance to BCR-ABL TKIs and the therapeutic strategies: A review. | Crit Rev Oncol Hematol | 2015 | https://conductscience.org/library/papers/25500000 | PubMed |
| 12 | 36561525 | Alterations in cellular metabolisms after TKI therapy for Philadelphia chromosome-positive leukemia in children: A review. | Front Oncol | 2022 | https://conductscience.org/library/papers/36561525 | PubMed |
| 13 | 34425075 | Chronic myeloid leukaemia. | Lancet | 2021 | https://conductscience.org/library/papers/34425075 | PubMed |
| 14 | 23121646 | Trends in chronic myeloid leukemia incidence and survival in the United States from 1975 to 2009. | Leuk Lymphoma | 2013 | https://conductscience.org/library/papers/23121646 | PubMed |
| 15 | 32127639 | European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. | Leukemia | 2020 | https://conductscience.org/library/papers/32127639 | PubMed |
| 16 | 36707619 | Management of children and adolescents with chronic myeloid leukemia in blast phase: International pediatric CML expert panel recommendations. | Leukemia | 2023 | https://conductscience.org/library/papers/36707619 | PubMed |
| 17 | 21234820 | Excellent outcomes of children with CML treated with imatinib mesylate compared to that in pre-imatinib era. | Int J Hematol | 2011 | https://conductscience.org/library/papers/21234820 | PubMed |
| 18 | 29498925 | Dasatinib in Pediatric Patients With Chronic Myeloid Leukemia in Chronic Phase: Results From a Phase II Trial. | J Clin Oncol | 2018 | https://conductscience.org/library/papers/29498925 | PubMed |
| 19 | 22207416 | Population pharmacokinetic and exposure-response analysis of nilotinib in patients with newly diagnosed Ph+ chronic myeloid leukemia in chronic phase. | Eur J Clin Pharmacol | 2012 | https://conductscience.org/library/papers/22207416 | PubMed |
| 20 | 20072833 | Dasatinib. | Recent Results Cancer Res | 2010 | https://conductscience.org/library/papers/20072833 | PubMed |
Cited by5
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 6 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42738405 | Long-Term Offspring Outcomes Following Parental Exposure to BCR::ABL1 Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: A Retrospective Cohort Study with Follow-Up to 24.6 Years. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/42738405 | PubMed |
| 42115566 | Dasatinib-Associated Chylothorax: A Scoping Review and Pharmacovigilance Analysis. | Ther Innov Regul Sci | 2026 | https://conductscience.org/library/papers/42115566 | PubMed |
| 41901263 | Design, Synthesis, and Biological Evaluation of N,N-Diphenylaniline-Based Derivatives as Antiproliferative Agents and ABL TK Inhibitors Against CML. | Pharmaceuticals (Basel) | 2026 | https://conductscience.org/library/papers/41901263 | PubMed |
| 41675902 | Redefining pediatric leukemia care - innovations in risk assessment and targeted treatment: a narrative review. | Ann Med Surg (Lond) | 2026 | https://conductscience.org/library/papers/41675902 | PubMed |
| 41496461 | Predictors of Response to Imatinib Therapy and Long-Term Outcomes in Paediatric and Adolescent Patients With Chronic Myeloid Leukaemia. | Cancer Rep (Hoboken) | 2026 | https://conductscience.org/library/papers/41496461 | PubMed |
Genes3
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| ABL1 | 25 | PubTator's text mining | https://conductscience.org/library/genes/25 | NCBI Gene |
| GH1 | 2688 | PubTator's text mining | https://conductscience.org/library/genes/2688 | NCBI Gene |
| IGF1 | 3479 | PubTator's text mining | https://conductscience.org/library/genes/3479 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39005125
GET https://conductscience.org/api/papers/v1/39005125/references?page=2